PharmaLex obtains rapid CE marking for a medical device that opens up a market worth $2.2 billion

  • A US-based company had developed a Class III medical device for the treatment of hepatic cancer. The device had been designed to be used with a specific medicinal product. The company wanted to sell their product in the EU and the product must therefore carry a CE mark.